Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) has issued an announcement.
BioDlink International Company Limited has announced the current composition of its board of directors and clarified the roles and functions of each member. The company has also detailed the makeup of its four key board committees—Audit and Connected Transactions Review, Remuneration, Nomination and Strategy and ESG—assigning chairperson and member responsibilities among its executive, non-executive and independent non-executive directors, underscoring its focus on structured corporate governance.
The Audit and Connected Transactions Review Committee will be chaired by independent non-executive director Xin Fan, while the Strategy and ESG Committee will be led by independent non-executive director Ulf Grawunder. Executive chairperson Dr. Jincai Li and non-executive director Xiaojie Xi will serve in various committee member roles, indicating a distribution of oversight duties intended to balance management input with independent supervision.
More about TOT BIOPHARM International Co. Ltd.
BioDlink International Company Limited, listed in Hong Kong under stock code 1875, operates in the biopharmaceutical sector. The company is overseen by a board that includes an executive chairperson, a non-executive director and several independent non-executive directors, reflecting a governance structure aligned with Hong Kong listing standards.
Average Trading Volume: 2,431,970
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.57B
See more data about 1875 stock on TipRanks’ Stock Analysis page.